• AMPK, Mitophagy, and Inflammation in Diabetic Periodontium

  2026-08-25

  The 2026 FASEB Journal study identifies AMPK as an upstream coordinator linking PINK1/Parkin-mediated mitophagy with NLRP3-driven inflammation in mechanically loaded periodontal tissue. Its in vivo and in vitro evidence indicates that high glucose suppresses mitochondrial quality control, whereas targeted AMPK activation restores mitophagy and reduces inflammatory signaling.

• N6-Methyl-dATP: From Fidelity to AML Strategy

  2026-08-25

  N6-Methyl-dATP offers translational researchers a substrate-level way to study polymerase selectivity, methylation-dependent DNA synthesis, and genomic stability in the context of AML biology. This article connects nucleotide chemistry with the LMO2/LDB1 axis and provides a practical framework for moving from biochemical validation to disease-relevant hypotheses.

• Palmitic acid: Practical Protocol and QC Guide

  2026-08-24

  Palmitic acid (hexadecanoic acid, SKU N2456) provides a characterized saturated long-chain fatty acid for solvent-based studies of lipid handling, protein palmitoylation, and metabolic signaling. It is suitable when ethanol or DMSO preparation and matched vehicle controls can be managed, but it is not appropriate for direct aqueous dissolution or long-term storage of prepared solutions.

• Gefitinib (ZD1839) as an EGFR Pathway Probe

  2026-08-24

  Explore how Gefitinib (ZD1839) can serve as a causal EGFR signaling probe in cancer and blue-light skin-barrier models. This article connects pathway pharmacology with orthogonal assay design, translational interpretation, and practical handling considerations.

• EZ Cap™ Human PTEN mRNA Workflow Guide

  2026-08-23

  Use EZ Cap™ Human PTEN mRNA to restore transient PTEN expression in cancer models, benchmark delivery systems, and interrogate the PI3K/Akt signaling pathway. This practical guide connects Cap 1/poly(A) design with cell-based assays and the HA-LNP transdermal strategy reported for melanoma research.

• Calpain Inhibitor I, ALLN: Practical Protocol

  2026-08-22

  Calpain Inhibitor I, ALLN (SKU A2602) provides a defined inhibitor profile for laboratory studies of calpain- and cathepsin-associated proteolysis in apoptosis, inflammation, and ischemia-reperfusion workflows. It should be used as a research reagent with appropriate vehicle, precipitation, cross-reactivity, and endpoint controls, not for diagnostic, therapeutic, or medical applications.

• 2-DG in Oral Lichen Planus: T-Cell Metabolism

  2026-08-22

  The reference study identifies glycolytic dependence in oral lichen planus-derived T cells and shows that 2-Deoxy-D-glucose reduces their capacity to trigger keratinocyte apoptosis. Its combination with rapamycin further suppresses T-cell activity, providing a mechanistic rationale for studying immunometabolic intervention in oral lichen planus while remaining limited to cellular and ex vivo evidence.

• Octenidine (dihydrochloride) Assay Guide

  2026-08-21

  This scenario-driven guide explains how Octenidine (dihydrochloride), SKU C6432, can be handled and interpreted in cell viability, proliferation, cytotoxicity, and antimicrobial research workflows. It connects formulation data, membrane-disruption biology, assay controls, and vendor-selection criteria to improve experimental consistency without overstating product-specific biological potency.

• T-5224 Induces Ferroptosis in Multiple Myeloma

  2026-08-20

  The reference study identifies ferroptosis, rather than apoptosis alone, as a mechanism by which the AP-1 inhibitor T-5224 suppresses multiple myeloma cells. Its rescue experiments connect T-5224 activity to reduced PI3K/AKT signaling and decreased GPX4 and SLC7A11, providing a mechanistic basis for investigating AP-1 inhibition alongside bortezomib.

• Salvianolic Acid B, LH2, and Pulmonary Fibrosis

  2026-08-20

  The reference study identifies Salvianolic acid B, also known as Dan Shen Suan B, as a natural product that suppresses LH2 expression and reduces pathological collagen remodeling in pulmonary fibrosis models. Its integrated cell and tissue evidence connects LH2 modulation with inhibition of EMT, FMT, Wnt/β-catenin signaling, collagen deposition, and loss of lung architecture.

• Beyond B Cells: Translating Ibrutinib Mechanisms

  2026-08-19

  Ibrutinib (PCI-32765) offers a powerful framework for interrogating BTK-dependent biology, from B-cell receptor signaling inhibition and chronic lymphocytic leukemia research to biomarker-led studies inspired by ATRX-deficient glioma research. This article separates established evidence from forward-looking hypotheses and provides a practical strategy for translational validation.

• Tropifexor (LJN452) Workflow for FXR Studies

  2026-08-19

  Tropifexor (LJN452) enables low-nanomolar interrogation of FXR signaling in intestinal barrier, liver, and metabolic disease models. This practical workflow combines dose-response design with compartment-aware metabolic readouts inspired by recent triacetin research.

• BMS 309403 and the FABP4 Atherosclerosis Axis

  2026-08-18

  A translational framework for using BMS 309403 to connect FABP4-driven lipid handling, inflammation, foam-cell biology, and cardiometabolic disease models.

• MHY1485: Practical mTOR Activator Workflows

  2026-08-18

  MHY1485 provides a controllable way to activate mTOR while interrogating autophagy, lipid metabolism, and ovarian follicle models. This guide connects product handling with assay design, quantitative controls, and troubleshooting strategies for reproducible cell and ex vivo experiments.

• LINC01278, mTOR Signaling, and Uveal Melanoma

  2026-08-17

  The reference study identifies LINC01278 as an autophagy-related long noncoding RNA that suppresses uveal melanoma progression through inhibition of the mTOR signaling pathway. By combining bioinformatics, pharmacological pathway perturbation, cellular assays, and a xenograft model, the work connects a prognostic RNA candidate with a testable tumor-suppressive mechanism.

8662 records 1/578 page Next 12345 下5页 Last page